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Background. Studies have demonstrated that self-testing for human immunodeﬁciency virus (HIV) is highly
acceptable among individuals and could allow cost savings, compared with provider-delivered HIV testing and coun-
seling (PHTC), although the longer-term population-level effects are uncertain. We evaluated the cost-effectiveness
of introducing self-testing in 2015 over a 20-year time frame in a country such as Zimbabwe.
Methods. The HIV synthesis model was used. Two scenarios were considered. In the reference scenario, self-
testing is not available, and the rate of ﬁrst-time and repeat PHTC is assumed to increase from 2015 onward, in line
with past trends. In the intervention scenario, self-testing is introduced at a unit cost of $3.
Results. We predict that the introduction of self-testing would lead to modest savings in healthcare costs of $75
million, while averting around 7000 disability-adjusted life-years over 20 years. Findings were robust to most vari-
ations in assumptions; however, higher cost of self-testing, lower linkage to care for people whose diagnosis is a con-
sequence of a positive self-test result, and lower threshold for antiretroviral therapy eligibility criteria could lead to
situations in which self-testing is not cost-effective.
Conclusions. Thisanalysissuggeststhatintroducingself-testingofferssomehealthbeneﬁtsandmaywellsavecosts.
Keywords. HIV; self-testing; cost-effectiveness; mathematical modeling; diagnostic.
In recent years, the scale up of antiretroviral therapy
(ART) in low-income countries has been dramatic,
helping transform human immunodeﬁciency virus
(HIV) infection from a terminal illness to a chronic
condition. Nevertheless, more than 50% of people living
with HIV remain unaware of their HIV status [1].They
are therefore unable to beneﬁt from HIV care and ART
and to take action to reduce their risks of transmitting
HIV. There are many reasons some people decide not
to actively seek an HIV test, including fear of stigma
discrimination, perceived lack of conﬁdentiality, incon-
venience and costs associated with accessing testing [2].
Some of these barriers relate particularly to current pro-
vider-based models of testing (eg, standard voluntary
counseling and testing [VCT] and provider-initiated
testing and counseling) and may be at least partially
overcome through use of self-testing for HIV [3]i f
this were available as an alternative.
Self-testing involves individuals collecting and testing
theirown samples (typicallysaliva) without the involve-
ment of a healthcare professional. Possible advantages
of self-testing over more-standard provider-delivered
HIV testing and counseling (PHTC) include greater
convenience, conﬁdentiality, and empowerment for
users. Self-testing has potential to reach people who,
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 for a variety of reasons, have chosen not to have an HIV test,
using the PHTC option. Its availability may also lead to an
increase in the frequency at which individuals choose to test
for HIV.
A number of self-test kits remain under development by
manufacturers. The costs of the kits themselves are likely to
be slightly higher than for equivalent kits used in clinical set-
tings, mainly because of the need for packaging and associated
marketing. However, overall, the cost per test of self-testing is
expected to be less than with PHTC, owing to a lack of health-
careworker involvement at the time of screening [4].This needs
to be balanced against possible disadvantages of self-testing, in-
cluding a sensitivity that is likely to be lower than that of PHTC
[5], the need foraconﬁrmatory PHTC fora deﬁnitive HIV-pos-
itive diagnosis, the potential for linkage to posttest care to be
less likelyor lesstimely, as well as possible adverse psychological
impacts due to receiving a HIV-positive result without the di-
rect support of a trained counselor.
In 2012, the US Food and Drug Administration (FDA) ap-
proved the OraQuick In-Home HIV Test as the ﬁrst HIV self-
test kit. The kit is sold over the counter in the United States for
$40. In low-income countries, regulated self-test kits are gener-
ally not available. Donors and stakeholders are evaluating
whether investments should be made to support the develop-
ment, promotion, and marketing of self-tests in low-income
countries. Preliminary research conducted in Kenya and Mala-
wi showed that acceptability and uptake is high, that accuracy is
relatively good, and that there are interventions that appear to
be effective in linking self-testers to HIV care [6–10].
Mathematical models offer a framework for evaluating the
balance of the advantages and disadvantages of self-testing.
Hence, they can provide insights into the potential net costs
and health effects of self-testing at a population level over the
longer term and can help determine whether introducing free
or subsidized self-testing would be cost-effective. The aim of
this study is to assess the potential cost-effectiveness and exam-
ine the main drivers of introducing self-testing in the general
population over 20 years in a low-income countries such as
Zimbabwe.
METHODS
HIV Synthesis Transmission Model
We used an updated version of the HIV Synthesis Transmission
Model, an individual-based stochastic model of HIV transmis-
sion and infection progression and treatment among heterosex-
uals that has been previously described [11–13].All variables in
the model are updated in 3-month intervals. The model in-
cludes an age structure, and sexual risk behavior is modeled
as the number of short-term partners with whom sex is con-
domless and the presence of a long-term partner with whom
sex is condomless in each period. In any given period, the
probability of an HIV-negative person having condomless sex
with a partner who is HIV-positive depends on the number
of sex partners of the HIV-negative partner and on the preva-
lence of HIV among the sex partners, accounting for patterns of
age mixing. Given exposure to an HIV-positive sex partner, the
probability of transmission depends on the viral load of the
partner (obtained by sampling from the distribution of viral
loads in partnerships formed by HIV-positive people, account-
ing for gender and age), on the estimated risk of transmission at
that viral load, on the presence of a concurrent sexually trans-
mitted infection, and on gender. For people who have become
infected with HIV, the variables modeled include their viral
load and CD4
+ T-cell count, whether resistance mutations are
present in their viral population, their risk of AIDS and death,
whether they have tested positive for HIV, whether they are
linked to care, whether they are remaining in care, and whether
they are receiving treatment, if eligible. The model of progres-
sion of HIV and the effect of ART has been shown to provide a
generally close ﬁt to observed data relating to the natural pro-
gression of HIV infection and the effect of ART [12,14].So that
observed trends in testing and the proportion of infected indi-
viduals receiving a diagnosis can be mimicked, people within
the model who have not tested positive for HIV and who
have access to HIV testing have an increasing chance over cal-
endar years to be tested for HIV. In addition, pregnant women
can access HIV testing through antenatal clinics. Updates to the
model presented here, compared with the version of the model
previously published, include age and gender-speciﬁcr a t e so f
ﬁrst-time and repeat testing, including self-testing, and calibra-
tion to reﬂect HIV prevalence and age-speciﬁc and gender-
speciﬁc levels of testing observed in Zimbabwe (Supplementary
Materials)[ 15]. The model was programmed in SAS software,
version 9.3 (SAS Institute, Cary, North Carolina).
Scenarios Modeled
The HIV epidemic in Zimbabwe is simulated until 2015 on the
basis of existing data on HIV prevalence and HIV testing [15].
From 2015, we compare two possible base case scenarios: a ref-
erence scenario, in which self-testing is not introduced and
there is continued reliance on PHTC alone, and the self-testing
scenario, in which self-testing is made available to the general
population aged 15–65 years from 2015 onward. In the refer-
ence scenario, the rates of ﬁrst-time and repeat testing increase
linearly by 0.5% per year (the proportion tested for HIV in the
last year is 39% in 2015, increasing up to 48% in 2035), and the
rates of being linked to care, being retained in pre-ART care,
and initiating ART, if eligible, remain the same as they were be-
fore 2015. One single simulation run was performed up to 2015,
while several hundred runs were simulated for the two scenarios
from 2015 through 2035, with means taken to limit stochastic
effects (the extent of uncertainty due to stochastic effects is
conveyed by providing 95% conﬁdence limits).
2 ￿ JID ￿ Cambiano et al
 
a
t
 
U
n
i
v
e
r
s
i
t
y
 
C
o
l
l
e
g
e
 
L
o
n
d
o
n
 
o
n
 
J
u
n
e
 
1
7
,
 
2
0
1
5
h
t
t
p
:
/
/
j
i
d
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 The introduction of self-testing is assumed to have 3 main
effects: (1) halving of the population unwilling to receive an
HIV test (from 5% to 2.5%), (2) substituting 10% of ﬁrst-
time and 30% of repeat PHTC with self-tests, and (3) increasing
t h er a t eo fﬁrst-time and repeat testing by 20%, owing to the
availability of self-testing. The availability of self-testing is not
assumed to affect PHTC in antenatal care settings. These as-
sumptions are based on limited current evidence but, overall,
are believed to be conservative in estimating the potential ben-
eﬁts of self-testing.
Additional Assumptions
The sensitivity and speciﬁcity of self-testing were assumed to be
92% and 99%, respectively, as observed in the studies leading to
FDA approval of the OraQuick In-Home HIV Test [16]. Vari-
ability across studies has been observed in the sensitivity of the
OraQuick In-Home HIV Test, mainly reﬂecting the models and
approaches used for HIV self-testing and the population of in-
dividuals who tested for HIV. High accuracy (99.2%) has been
found both in studies that offered supervised self-testing [6]and
studies characterized by a lower level of supervision [10,17,18].
To our knowledge, only one study reported a lower accuracy
than that identiﬁed in the OraQuick FDA studies [19], and
this was due to the lackof information given on how to interpret
a faint positive result and to the fact that people receiving ART
were self-testing. It is known that ART may decrease the overall
sensitivity of oral ﬂuid-based self-testing [19, 20]. In this anal-
ysis, we assumed that only people who had an unknown HIV
status (and were therefore not receiving ART) could use self-
testing.
PHTC was considered more accurate, with a sensitivity esti-
mated to be 98% [21] and a speciﬁcityof 100% (given conﬁrma-
tory testing, when a person is found to be HIV positive, it is
unlikely that a person receives a diagnosis of HIV infection if
they are not infected).
Once a person receives a positive self-test result, a conﬁrma-
tory PHTC was assumed to be necessary to consider a person as
having a diagnosis of HIV infection, as well as the possibility of
linking that person to care (ie, where they receive an ART-
eligibility assessment) and eventually initiating ART. The proba-
bility of a conﬁrmatory PHTC by 1 year following a positive self-
test result was assumed to be 0.8, based on evidence that, in the
context of supervised self-testing, most people disclose to their
counselor [10]. Once the person receives a diagnosis (following
a positive PHTC result), the probability of being linked to care
was assumed to be 0.6 within 1 year after diagnosis [22],regard-
less of whether they initially underwent self-testing or PHTC.
No change in the frequency of condomless sex among people
who tested negative for HIV was assumed, whereas those who
tested positive for HIV reduced the frequency of condomless
sex with casual partners by 17% in the ﬁrst 6 months (and by
9% afterward) and by 13% with long-term partners, regardless
of the type of HIV test. In the context of VCT, there is evidence
that this is the case [23], and in the base case we assume that
this holds for self-testing, although we are assuming quite a
small effect. People were assumed to be eligible for ART when
their CD4
+ T-cell count decreased to below 500 cells/mm
3 in
the base case, in line with guidelines in Zimbabwe [24]a n d
from the WHO [25]. Implementation of prevention of mother-
to-child-transmission option B+ (ie, provision of lifelong ART
for pregnant and breast-feeding women) was not taken into
account.
Economic Analysis
The two scenarios (the reference scenario and the self-testing
scenario) were compared on the basis of their costs and health
outcomes, which are both discounted to present values at 3%
per annum, from a healthcare perspective [26].Costs were esti-
mated on the basis of resource use (eg, number of tests and
numberof clinicvisits) and associated unit costs. The fully load-
ed cost of a PHTC was assumed to be $9 fora negative test result
and $25 for a positive test result or a conﬁrmatory test following
a positive self-test result, so that the average cost was around $10
[27]. The fully loaded cost of self-testing was assumed to be $3
per unit. Health outcomes were summarized in the form of dis-
ability-adjusted life-years (DALYs) averted, which captures
changes in both mortality and morbidity, including the impact
on onward HIV transmission (Supplementary Materials)[ 28].
Resultsarepresentedacrossarangeofcost-effectivenessthresh-
olds (CETs) from $0 (an extreme case, implying a health system
would only be concerned with reducing costs) to $10000 (a rela-
tively high threshold only likely to be relevant in well-ﬁnanced
health systems with full coverage of interventions offering health
gains at less than this amount).
Costs and health outcomes were rescaled to provide ﬁgures
relevant to the entire adult population (15–65 years old) of
Zimbabwe. Because of the stochastic variation inherent in
the model, a high number of simulations were required, so ﬁg-
ures are presented on a discrete scale, rather than a continuous
scale.
Sensitivity Analyses
The following parameters were varied in univariate sensitivity
analyses: the cost of self-testing, the sensitivity of self-testing,
the probability of PHTC as a direct consequence of a positive
self-test, the probability of being linked to care by 1 year after
a positive PHTC result (whether prompted by a self-testing or
not), and the reduction in the frequency of condomless sex for
those receiving a diagnosis on the basis of a positive self-test
result, eligibility criteria to initiate ART, the magnitude of the
increase in the rates of ﬁrst and repeat testing due to the intro-
duction of self-testing, and the level of substitution of self-test-
ing for PHTC. The most determinant parameters of cost-
effectiveness were also varied in multivariate analyses.
Cost-effectiveness of HIV Self-Testing ￿ JID ￿ 3
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 RESULTS
Introduction of self-testing, as assumed in the base case scenar-
io, led in 2035 to a 7% higher proportion tested for HIV in the
past year, compared with the reference scenario (57% vs 50%;
Table 1). The total discounted costs over 20 years for HIV test-
ing and resulting HIV care and ART under the reference sce-
nario base case assumptions is estimated to be almost $3.1
billion (Figure 1). Of this, 40% is attributable to the cost of
antiretroviral drugs, around a quarter to the cost of clinic visits,
and 24% to the cost of PHTC. Over a 20-year period, the self-
testing scenario is predicted to lead to savings of $75 million
(95% conﬁdence interval [CI], $73 million–$77 million), for a
cost reduction of 2.6%, due primarily to lower testing costs.
The introduction of self-testing would also result in health
gains, with approximately 7000 DALYs averted (95% CI, 700–
13000 DALYs averted; Table 2).
Table 2 summarizes increments in total discounted costs and
total discounted DALYs averted with the self-testing scenario,
compared with the reference scenario, along with the cost-
effectiveness of self-testing, under the base case and alternative
assumptions in sensitivity analyses. This is provided for different
CETs. In general, for any scenario in which DALYs are averted,
the probability that self-testing is cost-effective will increase with
increasing CETs, because at some point the cost of the DALYs
averted becomes affordable. In contrast, for scenarios that lead
to a loss in DALYs, self-testing is less likely to be cost-effective
with increasing CETs because at some point the money saved
from the self-testing scenario is not worth the loss in DALYs.
The results are particularly driven by the cost of self-testing itself.
Ifthecostofself-testingisthesameasthatofanegativeresultofa
PHTC-associated test ($9), it is not cost-effective at a CET of
$10 000 per DALY averted or less because it results in higher
costs ($136 million more than under the reference scenario)
but relatively small health gains. If, however, self-testing were
to cost $4 or less, then the self-testing scenario would be cost-
effective even at a CET of $500, keeping other base case assump-
tions ﬁxed (Figures 3 and 4).
The level of substitution of PHTC with self-testing affects the
results in a slightly counterintuitive way (Figure 2). At all CETs
considered ($1–$1000), the lower cost self-testing is preferred
even when the probability of PHTC following a positive self-
test result (and therefore the chance of receiving a diagnosis)
is low; this is the case even at relatively high CETs, because
even if the probability of PHTC as a direct consequence of
a positive self-test is low and the level of substitution high,
the cost savings outweighs the loss in health. Self-testing is
clearly more likely to be cost-effective as the cost of self-testing
decreases (Figures 3 and 4).
Regarding the levels of increase in the frequencies of under-
going an initial test and a repeat test due to the availability of
self-testing (Figure 4), we found that the greater the levels of
increase, the greater the total cost; however, this is counterbal-
anced by the dramatic cost savings due to the partial substitu-
tion of PHTC with self-testing.
Table 1. Predictions Over Time in the Reference Scenario and the Self-Testing Scenario
Variable 2011 DHS Data
a
Model Estimate
Baseline
Reference Scenario
Self-Testing
Scenario
2015 2025 2035 2025 2035
HIV prevalence, % 15 13 10 7 10 7
Ever tested for HIV, % 50 66 77 79 80 83
Tested for HIV in the past year, % 28 39 48 50 54 57
Received HIV infection diagnosis, % . . . 85 91 93 92 93
HIV-positive patients receiving ART, % . . . 56 66 69 66 69
Model estimates are median values of all simulations.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus.
a Demographic and Health Surveys (DHS) [15].
Figure 1. Total discounted cost over 20 years. Abbreviations: ART,
antiretroviral therapy; CD4, CD4
+ T-cell count; CTX, cotrimoxazole; PHTC,
provider-delivered human immunodeﬁciency virus testing and counseling;
RS, reference scenario; ST, self-testing; STS, self-testing scenario; WHO
3/4, treatment of World Health Organization stage 3 and 4 human immu-
nodeﬁciency virus disease [29].
4 ￿ JID ￿ Cambiano et al
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 Table 2. Cost-effectiveness for the Self-Testing Scenario (STS) and Reference Scenario (RS) Under Base Case Assumptions and
Alternative Assumptions and According to Cost-effectiveness Threshold
Variable
Cost-effectiveness Threshold, $ Total Discounted Change
in Costs,×$1 Million,
Compared With RS (95% CI)
Discounted DALYs Averted,
×1000, Compared With RS
(95% CI) 0 500 1000 5000 10000
Base case
a STS STS STS STS STS −75 (−77 to −73) 7 (.7–13)
Cost of ST, $9 (base case: $3) RS RS RS RS RS 136 (134–137) 7 (.7–13)
Sensitivity of ST, 0.55 (base case: 0.92) STS STS STS STS RS −81 (−84 to −79) −11 (−22 to −.5)
Probability of PHTC as a direct
consequence of a positive ST, 0.37
(base case: 0.8)
STS STS STS STS STS −87 (−90 to −84) 0.1 (−11 to 11)
Linkage to care following diagnosis for
those who had a ST of 0.4 by 1 y (base
case: 0.6)
STS STS STS RS RS −105 (−112 to −97) −19 (−32 to −6)
ART initiation at CD4 <350 cells/mm
3
(base case: CD4 <350 cells/mm
3
without introduction of ST)
STS STS STS RS RS −69 (−74 to −64) −21 (−40 to −2)
No reductionin condomlesssex following
a positive ST (base case: as PHTC)
STS STS STS STS STS −74 (−77;−70) 19 (6–33)
Increase in rate of first test due to ST (base case: 20%)
2.5% STS STS STS STS STS −82 (−85 to −79) 10 (−.6 to 20)
7.5% STS STS STS STS STS −81 (−85 to −78) 13 (−.6 to 26)
Increase in rate of repeat test due to ST (base case: 20%)
2.5% STS STS STS STS STS −102 (−105 to −99 4 (−6 to 14)
7.5% STS STS STS STS STS −82 (−86 to −78) 13 (−1 to 26)
Substitution (base case: 30% for repeat test, 10% for first test)
5% for repeat test, 2% for first test RS RS STS STS STS 38 (34–41) 39 (20–57)
15% for repeat test, 5% for first test STS STS STS STS STS −12 (−17 to −7) 22 (5–39)
25% for repeat test, 8% for first test STS STS STS STS STS −52 (−57 to −47) 20 (.5–39)
The discounted total cost of the RS over 20 years from 2015 is $3168 million.
Abbreviations: ART, antiretroviral therapy; CD4, CD4
+ T-cell count; CI, confidence interval; DALY, disability-adjusted life-year; PHTC, provider-delivered human
immunodeficiency virus testing and counseling; ST, self-testing.
a See the “Scenarios Modeled” subsection in “Methods” section.
Figure 2. Cost-effective scenario under different assumptions of substitution and probabilityof provider-delivered human immunodeﬁciency virus testing
and counseling (PHTC) as a direct consequence of a positive self-testing (ST). Abbreviations: CET, cost-effectiveness threshold; F, substitution of PHTC with
self-testing during ﬁrst test; R, substitution of PHTC with self-testing during repeat test.
Cost-effectiveness of HIV Self-Testing ￿ JID ￿ 5
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 DISCUSSION
Self-testing holds the promise of expanding the reach of HIV
testing. It may enable some people to test who would not oth-
erwise choose PHTC because of stigma, conﬁdentiality, cost, or
other barriers to access. It may also increase the overall frequen-
cy of testing in the population, owing to greaterconvenience. As
the basis forafﬁrming HIV status, leading to linkage to care and
receipt of ART for those eligible, as well as prompting individ-
uals who learn they are HIV-positive to reduce the risks of on-
ward HIV transmission to others, the potential health gains
from self-testing are clear. What is more, self-testing may also
reduce costs, enabling savings in HIV testing programs that
can be reinvested in further expansion of testing or in delivery
of other HIV- and healthcare-related interventions.
Overall, under our base case assumptions, we estimate that
the introduction of self-testing will allow savings of around
$75 million over 20 years in Zimbabwe, with a low number of
DALYs averted (7000, in the context of an adult population of
7.5 million in mid-2013). If these assumptions hold in other set-
tings, self-testing should always be introduced, regardless of
how poorly or well resourced a health system is, because it
Figure 3. Cost-effective scenario under different assumptions of substitution and cost of self-testing (ST). Abbreviations: CET, cost-effectiveness thresh-
old; F, substitution of provider-delivered human immunodeﬁciency virus testing and counseling with self-testing during ﬁrst test; R, substitution of provider-
delivered human immunodeﬁciency virus testing and counseling with ST during repeat test.
Figure 4. Cost-effective scenario under different assumed increases in the rates of ﬁrst test and repeat test and cost of self-testing (ST). Abbreviation:
CET, cost-effectiveness threshold.
6 ￿ JID ￿ Cambiano et al
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 leads to a win-win situation involving better health outcomes at
reduced cost. If we assume a CET of $500 (similar to Zim-
babwe’s gross domestic product per capita in 2012), the $75
million savings could be used to avert at least 150 000 DALYs
by introduction of interventions with incremental cost-effec-
tiveness ratios of $500 or less per DALY averted. The monetary
value of introducing self-testing to Zimbabwe (ie, the net mon-
etary beneﬁt, calculated as follows: [health gains × CET] + cost
savings [30]) would be $78.5 million over 20 years, indicating
huge beneﬁts associated with supporting the availability of
self-testing in the country.
However, the population costs and health effects of self-testing
depend on a range of complex and interacting factors, and there
are plausible scenarios with characteristics such as an inadequate
cascade of care following self-testing that would result in worse
outcomes than those of the reference scenario.
Our sensitivity analyses provide insight into what determines
the magnitude of population health gains and suggest what pro-
grammatic recommendations may support optimal implemen-
tation of self-testing. First, the cost of self-testing relative to that
of PHTC appears to be the most important factor determining
cost-effectiveness, particularly at lower CETs. The OraQuick
HIV test kit designed for clinical use was sold for $4 in low-
income countries in 2005 [31]. Lower-cost alternatives to self-
testing would lead to additional gains if these were to become
available. The cost of distributing self-tests cannot be ignored,
but it is expected to be signiﬁcantly lower than the cost of pro-
viding PHTC. To the best of our knowledge, data on the cost of
rolling out self-testing are not currently available, and the only
study conducted in sub-Saharan Africa evaluating the uptake of
self-testing distributed the kit through community counselors
[8].Second, we evaluated the impact of introducing self-testing
in addition to PHTC in a setting such as Zimbabwe, with a high
level of HIV diagnosis and ART coverage; in 2015, before the
introduction of self-testing, an estimated 85% of people with
HIV receive a diagnosis. It is likely that the impact of introduc-
ing self-testing would be even greater as the proportion of peo-
ple with HIV infection that is undiagnosed increases. Third, in
some circumstances, self-testing may lead to improved health
outcomes but also to higher costs, compared with the reference
scenario, if the overall level of testing (ie, the increase in the rate
of ﬁrst-time and repeat testing) increases dramatically because
of the availability of self-testing. The few studies conducted so
far on uptake of self-testing have found it to be extremely ac-
ceptable [7–10]. Studies in Malawi, for example, have shown
that 76% of adults avail themselves of self-testing by 12 months
followingits introduction [10].In settings with higher CETs, the
potential for health improvement will usually outweigh higher
costs. Appropriate targeting of self-testing, for example, to pop-
ulations afﬂicted by a higher HIV prevalence or that are known
to be less likely to test for HIV, such as men in many countries,
is likely to be necessary in such situations. There is also a risk in
some circumstances that self-testing may lead to worse health
outcomes, such as at CETs of $5000 or more, if ART initiation
occurs at a CD4
+ T-cell count of <350 cells/μL or if the linkage
to care following a diagnosis prompted by a positive self-test is
low. This suggests that, to be translated into health gains, self-
testing needs to be accompanied by proactive interventions to
support a continuum of care following diagnosis. A study in
Malawi [8] investigated one scheme that could provide comple-
mentary beneﬁts—offering ART initiation at home among peo-
plewho self-test—and found that this signiﬁcantly increased the
probability of initiating ART within 6 months. Finally, there is
always potential for unintended adverse consequences associat-
ed with any public health intervention, so countries should
closely monitor their experiences with introducing self-testing.
Linkage to care, promoting counseling services, and reporting
of test outcomes need to be strengthened in support of such
public health interventions.
In conclusion, our results suggest that the introduction of
self-testing may not only be cost-effective, but also may be
cost saving under the assumptions described in the base
case scenario. Under these assumptions, self-testing should be
made available even in settings where resource-constraints
are greatest. Notably, in some circumstances, it may be neces-
sary to target self-testing to individuals who have certain risk
factors.
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